Perspective Therapeutics, Inc. (AMEX: CATX) is a Healthcare company (Medical - Devices) with a market capitalization of $104M. The Maz Rating grades it against the other companies in its sector.
Perspective Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.86, Perspective Therapeutics, Inc. trades at 580.9x sales and 0.3x book value. Over the last twelve months it generated about $178767 of revenue and a net loss of $181M. It runs a gross margin of -536.2%, an operating margin of -74402.8% and a net margin of -69439.0%. It shows return on equity of -41.9%, return on invested capital of -40.1% and a free cash flow yield of -133.9%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 5.18. Over the past 52 weeks the share price ranged from $0.78 to $6.16, with a beta of 1.99.
Perspective Therapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 9 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.